Spring Bank Pharmaceuticals Announces Presentation of Results from Phase I Clinical Trial Supporting the Novel Mechanism of Action of SB 9200 in Patients with Hepatitis C at The Liver Meeting®

MILFORD, Mass., Oct. 13, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, today announced that a poster presentation describing results from a Phase 1 clinical trial of SB 9200 in patients with hepatitis C will be presented at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), to be held on November 13-17, 2015 at the Moscone Convention Center in San Francisco.

The details for the poster presentation are as follows:

Date & Time: Tuesday, November 17 from 8:00 a.m. to 12:00 p.m. Pacific Time
Poster Title: SB 9200 Shows Antiviral Activity Against HCV-RNA by Targeting Host Cytosolic Sensor Proteins RIG-I and NOD-2 to Activate IFN Signaling Pathways
Abstract Number: 2262
Session Title: Therapeutics: Preclinical and Early Clinical Development
Location: Moscone West

The full abstract can be viewed here.

About SB 9200

SB 9200, derived from Spring Bank's proprietary Small Molecule Nucleic Acid Hybrid (SMNH) technology platform, is a novel anti-viral agent that uniquely acts by modulating the host immune response to viral infections through activation of the intracellular sentinel proteins RIG-I and NOD2. SB 9200 is being developed for the treatment of hepatitis B, RSV and hepatitis C infections.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical stage biopharmaceutical company. Based on its proprietary SMNH chemistry platform, Spring Bank is developing a pipeline of products representing a new class of pharmaceuticals with a wide range of applications. These rationally designed molecules combine the selectivity of naturally occurring nucleotides with the drug-like properties of classical pharmaceuticals.  The SMNHs have the properties of oral delivery, good pharmacokinetic profile, low side effects and ease of manufacture. The Company's most advanced clinical candidate, SB 9200, is a potential breakthrough drug for the treatment for HBV, RSV and HCV and other viral diseases. SB 9200 has a novel mechanism of action that involves modulation of the host immune response in the presence of viral infection. 

Contact:
Maeve Conneighton
Argot Partners
(212) 600-1902
[email protected]

SOURCE Spring Bank Pharmaceuticals, Inc.

Related Links

http://www.springbankpharm.com